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Resumo 
A Niemann-Pick tipo C (NPC) é uma doença metabólica rara com um 
envolvimento neurológico e visceral, caracterizada por uma acumulação anormal de 
lípidos (colesterol e esfingolípidos) no sistema endossomal e lisossomal. Mutações 
pontuais nas proteínas NPC1 ou NPC2, envolvidas no transporte de lípidos na via 
endocitica, parecem ser fundamentais para o aparecimento desta patologia. Células 
de Saccharomyces cerevisiae sem a proteína Ncr1p, o homólogo em levedura da 
proteína NPC1 de mamíferos, apresentam uma maior sensibilidade a peróxido de 
hidrogénio, um tempo de vida mais curto e disfunções mitocondriais associadas com 
acumulação de bases esfingóides de cadeia longa. Os mutantes ncr1Δ também 
acumulam diversas espécies de ceramida, levando à ativação da proteína 
serina/treonina fosfatase Sit4p, homologa da proteína fosfatase 6 humana. 
Consistentemente, verificou-se que a atividade desta fosfatase aumenta no modelo de 
levedura de NPC1 e a sua deleção suprime os defeitos mitocondriais e tempo de vida 
reduzido de células ncr1Δ. 
Este trabalho teve como objetivo desvendar o papel do Sit4p na regulação do 
metabolismo de esfingolípidos e nas disfunções mitocondriais de células ncr1Δ. Para 
isso avaliámos alterações na transcrição de genes que codificam Lac1p e Lag1p, 
componentes do complexo ceramida sintetase, e Ydc1p e Ypc1p, duas ceramidases, 
em células transformadas com repórteres lacZ. Os nossos resultados mostram que a 
expressão destes genes está aumentada em células ncr1Δ por mecanismos 
dependentes da Sit4p. No entanto, a deleção do LAG1 ou YDC1 nestas células não 
restaurou a função mitocondrial, visto que os duplos mutantes são incapazes de 
crescer em fontes de carbono não fermentativas. O tratamento de células ncr1Δ com 
miriocina, um inibidor da serina-palmitoiltransferase, também não suprimiu as 
disfunções mitocondriais.  
A autofagia é crucial para a homeostasia celular e função mitocondrial, mas 
está alterada em células de NPC1. Estas células também apresentam valores 
aumentados de catepsina D, uma protease lisossomal. Estes fenótipos estão 
conservados no modelo de levedura, já que células deficientes em Ncr1p apresentam 
um aumento basal da autofagia e da atividade da Pep4p, um homólogo da catepsina D, 
dependentes da Sit4p. Estes resultados sugerem que a ativação do Sit4p medeia 
alterações no metabolismo de esfingolípidos, autofagia e longevidade em células 
ncr1Δ. A Sit4p também funciona abaixo do TORC1 (Target of rapamycin complex 1), 
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um regulador do metabolismo de esfingolipidos, da autofagia e do envelhecimento em 
levedura. A deleção do gene TOR1 aumentou a longevidade e a resistência a peróxido 
de hidrogénio de células ncr1Δ. Estes resultados implicam a Sit4p e o TORC1 nas 
disfunções mitocondriais e envelhecimento prematuro do modelo de levedura da 
doença NPC1. 
Palavras chave: Niemann-Pick tipo C1, Ncr1p, esfingolípidos, autofagia, TORC1, 
Sit4p, função mitocondrial 
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Abstract 
The Niemann-Pick Type C (NPC) is a rare metabolic disease with neurological 
and visceral involvement, characterized by an abnormal accumulation of lipids 
(cholesterol and sphingolipids) in the late endosomal/lysosomal network.  Point 
mutations in either NPC1 or NPC2, which are involved in lipid transport through the 
endocytic pathway, seem to be instrumental for the onset of this pathology. 
Saccharomyces cerevisiae cells lacking Ncr1p, the yeast homolog of mammalian 
NPC1, present higher sensitivity to hydrogen peroxide, shortened chronological 
lifespan and mitochondrial dysfunctions associated with the accumulation of long chain 
sphingoid bases. The ncr1 mutants also accumulate several ceramide species, 
leading to activation of the serine threonine protein phosphatase Sit4, an homolog of 
human protein phosphatase 6. Consistently, the activity of this phosphatase was also 
shown to be increased in the yeast model of NPC1, and its deletion suppressed the 
mitochondrial defects and shortened lifespan of ncr1 cells.  
This work aimed to disclose the role of Sit4p is the regulation of sphingolipid 
metabolism and mitochondrial dysfunctions of ncr1 cells. For that we assessed 
changes in the transcription of genes encoding Lac1p and Lag1p, components of the 
ceramide synthase complex, and of Ydc1 and Ypc1, two paralogue ceramidases, in 
cells transformed with lacZ reporters. Our results show that expression of these genes 
was increased in ncr1 cells by mechanisms dependent on Sit4p. However, the 
deletion of LAG1 or YPC1 in ncr1 cells did not restore mitochondrial function as 
double mutants were unable to grow on a non-fermentable carbon source. Treatment 
of ncr1 cells with myriocin, an inhibitor of serine palmitoyltransferase, also did not 
suppress mitochondrial dysfunctions.  
Autophagy is crucial for cell homeostasis and mitochondrial function but is 
altered in NPC1 cells. These cells also show increased levels of cathepsin D, a 
lysosomal protease. This is conserved in the yeast model, since Ncr1p deficient cells 
exhibited Sit4-dependent increases in autophagy and in the activity of Pep4p, a 
homolog of cathepsin D. These results suggest that Sit4p activation mediates changes 
in sphingolipid metabolism, autophagy and lifespan in ncr1 cells. Sit4p also functions 
downstream of TORC1 (Target of Rapamycin Complex 1), a regulator of sphingolipid 
metabolism, autophagy and aging in yeast. The deletion of TOR1 increased the 
chronological lifespan and hydrogen peroxide resistance of ncr1 cells. The overall 
results implicate Sit4p and TORC1 in the mitochondrial dysfunctions and premature 
aging of the yeast model of NPC1. 
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1.1 Lysosomal storage diseases  
The late-endosome/lysosomal system comprehends a group of organelles and 
pathways required by cells in order to process and recycle various exogenous 
metabolites and macromolecules, which can then be transported to their respective 
cellular compartments where they will have a specific function (Winchester, Vellodi et al. 
2000). An impairment of this pathway, caused by a genetic defect in a luminal or 
membrane protein for instance, can many times result in the accumulation of molecules 
in lysosomes and other vesicles. These can be lipids or proteins and their excessive 
storage can be highly detrimental to the cell, leading to deficiencies in any human 
organ or tissue. Diseases associated with these phenotypes can lead to a class of rare, 
inherited heterogeneous group of disorders called lysosomal storage diseases (LSDs) 
(Winchester, Vellodi et al. 2000). This group of diseases, which affects mostly children 
of a young age, has a significant incidence on the Northern Portuguese population (25 
per 100 000 live births) when compared to other countries, so the study of the 
molecular and genetic mechanisms underlying them are of high importance (Pinto, 
Caseiro et al. 2004). Examples of this disease’s include Farber’s disease, Hunter 
syndrome and, under focus on this thesis, Niemann-Pick type C. 
1.2 Niemann-Pick type C 
The Niemann-Pick disease, a condition first described in the late nineteen 
twenties by Albert Niemann and Ludwig Pick, comprehends a group of autosomal 
recessive disorders caused by lipid storage abnormalities in lysosomes (Vanier 2010). 
Although initially defined as a single pathology, it quickly became evident that its clinic 
expression was highly variable in patients, particularly in what regarded age of onset, 
lifespan and affected organs – while some presented mostly neurological symptoms, 
others had a more visceral (spleen, liver and sometimes the lung) involvement. These 
observations led Allan C. Crocker to first divide it into four main types (Crocker 1961): 
type A, related to an early acute central nervous system (CNS) impairment and a 
massive visceral accumulation of sphingomyelin; Type B, with a chronic course and no 
nervous system involvement; types C and D with moderate and slower course and 
minor visceral involvement. In terms of biochemical and molecular criteria, it became 
clear there was either a primary deficiency in acid sphingomyelinase (types A and B) or 
a defective transport and processing of low density lipoprotein-derived cholesterol (type 
C) (Vanier 2010). The latter is, therefore, a lipid trafficking disorder where unesterified 
cholesterol and other lipids accumulate in the endocytic pathway, particularly 
endosomes and lysosomes. 
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Niemann-Pick type C (NPC) quickly became a significant disease model, not 
only to develop therapeutic applications for it but also as a mean to better understand 
the metabolic impact of lipid accumulation in cells. It is an autosomal recessive, 
neurovisceral condition, caused by accumulation of cholesterol in the liver, spleen and 
brain (Pentchev, Comly et al. 1985, Pentchev, Brady et al. 1994). It has an estimated 
prevalence of 1:150,000 individuals and a birth prevalence that ranges from 0.66 to 
0.88 per 100,000 in countries like France, UK or Germany (Vanier and Millat 2003, 
Vanier 2010). At the cellular level, unesterified cholesterol accumulates in the late 
endosomal/lysosomal system, due to a trafficking defect of this sterol to other 
subcellular compartments. This disease also has a wide clinical spectrum at several 
levels: although most of the affected individuals are young children that end up dying 
very young, it also affects adults, and it has a great variety of symptoms. It involves not 
only an accumulation of unesterified cholesterol but also sphingolipids, gangliosides 
(mostly GM1 and GM2) and phospholipids within the cell’s endosome/lysosomal 
system (Chang, Reid et al. 2005). In Portugal, the incidence of this disease appears to 
be much higher, with 9 cases from 1986 to 2005, when compared to other countries 
(Pinto, Caseiro et al. 2004, Vanier 2010).  
1.2.1 Symptomatology 
There is a great variety of symptoms and phenotypes that usually affect patients 
with the disease, that include hepatic, neurological or psychiatric manifestations 
(Vanier and Millat 2003). Typical symptoms generally include cerebellar ataxia, 
dysarthria, dysphagia, and progressive dementia. Cataplexy, seizures and dystonia are 
other quite common features, and psychiatric disturbances are frequent in late-onset 
patients. However, the symptomatology of the affected subject varies according to the 
age of onset, which is wide. Infantile manifestations of the disease include 
hepatosplenomegaly, which consists in the enlargement of the liver and spleen, and 
respiratory failure. Young children with NPC may also show a deficient development of 
motor skills, many never learning to walk. Older children (6-15 years) show learning 
disabilities and clumsiness. In adults, the manifestations are mostly neurological and 
psychiatric. Psychosis is not uncommon, mostly through paranoid delusions or auditory 
or visual hallucinations. Patients also show depressive syndrome, behavioral problems, 
aggressiveness, and bipolar disorders, among others (Vanier 2010). 
1.2.2. Molecular genetics and the NPC proteins 
The onset of NPC is thought to be caused by point mutations in two genes: 
NPC1, which is involved in the majority of cases (95%), and NPC2, in only 5% of the 
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cases (Steinberg, Ward et al. 1994, Vanier, Duthel et al. 1996). The discovery of these 
mutations led to a subdivision between Niemann-Pick C1 and C2, according to the 
gene involved. The loss of function of either one of these proteins seems to be the 
underlying cause behind the disease and its phenotypes (Yu, Jiang et al. 2014). The 
NPC1 gene is localized in chromosome 18q11-12 and encodes a large integral 
glycoprotein found predominantly in the limiting membrane of late endosomes and 
lysosomes (Higgins, Davies et al. 1999, Ioannou 2005). Topological models have 
revealed that NPC1 has thirteen transmembrane helices and three large, glycosylated 
loops projecting into the lumen of the lysosome (Figure 1), which seems to be 
responsible for the correct recycling of cholesterol in vesicles (Yu, Jiang et al. 2014). 
The first of these domains is designated N-terminal domain (NTD) and appears to be 
the site for cholesterol binding, (Infante, Radhakrishnan et al. 2008).  
A cluster of five membrane spanning sequences of NPC1 share homology with 
the sterol-sensing domain (SSD), which is capable of binding sterols and is present in 
several key players of cholesterol homeostasis, namely 3-hydroxy-3-methyl-glutaryl-
CoA reductase and sterol regulatory element binding protein cleavage-activating 
protein (SCAP) (Davies and Ioannou 2000). This domain was later found to be required 
for NPC1 to bind several sterols, with point mutations in SSD diminishing this ability 
(Ohgami, Ko et al. 2004). NPC1 also contains a cysteine rich loop that may be 
important for protein-protein interactions. The defective efflux phenotype from late 
endosomes and lysosomes apparently drives an upregulation in cholesterol 
biosynthesis, which led some investigators to propose that this could also be the case 
for other membrane lipids like sphingolipids and gangliosides (Yiannis a Ioannou 2005). 
The NPC2 gene is localized in chromosome 14q24.3. It encodes a small, 
soluble, secreted and recaptured lysossomal glycoprotein that binds cholesterol with 
high affinity in a hydrophobic pocket (Vanier and Millat 2004). Mutations in either NPC1 
or NPC2 seem to lead to the same pattern of lipid accumulation (Sleat, Wiseman et 
al.2004), which indicates that these proteins seem to act in a cooperative fashion to 
take cholesterol out of the lysosomes to other cellular compartments. A hypothetical 
model proposes that cholesterol binds NPC2 in the lumen with its hydroxyl group 
exposed, and then it is transferred to the N-terminal domain of NPC1 by reversing its 
orientation (Kwon, Abi-Mosleh et al. 2009). NPC1 seems therefore to be important for 
cholesterol to “enter” the membrane.  
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Figure 1  - Model of NPC1 structure. This protein has thirteen transmembrane domains, five of which share homology 
to the SSD of other sterol metabolism enzymes, three large luminal loops, and a dileucine C-terminal motif (Yu, Jiang et 
al. 2014). 
1.2.3. Lipid involvement 
The accumulation of unesterified cholesterol in the late endosome/lysosomal 
system was one of the first cellular hallmarks described for the NPC disease, observed 
in cultured skin fibroblasts of NPC1 patients (Pentchev, Comly et al. 1985). Usually, 
after endocytosis and hydrolysis of esterified cholesterol in the lysosomes, cholesterol 
is delivered to other cellular compartments, like the endoplasmic reticulum (ER), Golgi 
apparatus, and the plasma membrane. In cells lacking NPC1, this process is 
apparently impaired, probably due to a disruption in the transport of free cholesterol 
from the lysosomes to other organelles. As consequence, although cholesterol is being 
accumulated, the cell is not able to sense it and therefore induces the synthesis of 
more cholesterol. The accumulation of cholesterol can lead to altered levels of other 
lipids – NPC cells also accumulate sphingomyelin, glycosphingolipids and bis-
(monoacylglycerol) phosphate. The accumulation of sphingomyelin seems to be due to 
a decreased activity of acid sphingomyelinase (Devlin, Pipalia et al. 2010). Another 
important phenotype is the accumulation of sphingosine in the liver and spleen of NPC 
patients (te Vruchte, Lloyd-Evans et al. 2004). It has also been reported that 
sphingosine accumulates in the acidic compartment of drug induced models of NPC1, 
leading to reduced levels of sphingosine-1-phosphate and low lysosomal calcium 
concentrations, the latter as a consequence of sphingosine accumulation (Lloyd-Evans, 
Morgan et al. 2008). Sphingosine is the most simple of sphingolipids, playing important 
roles in cell signaling (see point 1.3 below). 
The pattern of lipid accumulation appears to be different in the brain and 
visceral organs (Vanier 2010). In liver and spleen there is no predominant compound 
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and these organs accumulate unesterified cholesterol, glycolipids, sphingomyelin, 
sphingosine and sphinganine (Vanier 2010). In the brain significant alterations occur in 
glycosphingolipids, particularly gangliosides GM2 and GM3, glucosylceramide, 
lactosylceramide and GA2, all in gray matter (Vanier 1999). In fact, some studies have 
emphasized that brain lipid alterations occur essentially in this part of the brain, with the 
exception of a severe loss of galactosylceramide and other myelin lipids in the white 
matter of patients with infantile and late-infantile form of the disease (Vanier 1999). 
1.2.4. The yeast model of Niemann-Pick type C 
The budding yeast Saccharomyces cerevisiae is a unicellular fungus, commonly 
known as baker’s yeast, which has been widely used as a eukaryotic model to 
characterize cellular processes conserved in evolution. Yeast is genetically well defined, 
is easy to manipulate and has a relatively short generation time, comparing with 
mammalian cells. Furthermore, the publication of its complete genome sequence in 
April 1996 has turned yeast into a powerful tool for gene manipulation, like gene 
disruption, gene marking, mutation or gene dosage effects (Mager and Winderickx 
2005). This has facilitated the characterization of protein function, localization and 
interactions as well as the biological consequences of their loss of function. Notably, 
30% of human genes involved in disease have yeast orthologues, most of them being 
key components in metabolic pathways (Mager and Winderickx 2005). Thus, studies 
using yeast can contribute to our understanding of the molecular basis of diseases, 
including NPC. 
The NCR1 (NPC1-related gene 1) gene is the yeast orthologue of human NPC1 
(Berger, Hanson et al. 2005). Ncr1p shares 35% sequence identity with mammalian 
NPC1 (Malathi, Higaki et al. 2004) and is localized in the limiting membrane of the 
vacuole (Zhang, Ren et al. 2004), the equivalent of mammalian lysosome. Furthermore, 
this protein seems to transit through the biosynthetic vacuolar proteins sorting pathway. 
Importantly, Ncr1p was shown to be capable of suppressing ganglioside and 
cholesterol accumulation in mammalian NPC1 cells, which proves the functional 
equivalence of Ncr1p and NPC1. The SSD, NPC and cysteine rich domains are also 
conserved in yeast Ncr1p and the pleckstrin homology domain has several regions of 
similarity (Malathi, Higaki et al. 2004). A study revealed several pathways involved in 
NPC1 phenotypes. Among them, there is an up-regulation of histone deacetylase 
genes in cells lacking this protein (Munkacsi, Chen et al. 2011). Recently, Ncr1p-
deficient cells have been used as a model of NPC1 in yeast. These cells present higher 
sensitivity to hydrogen peroxide and reduced chronological lifespan, associated with 
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increased levels of oxidative stress markers, decreased anti-oxidant defenses and 
mitochondrial dysfunctions (Vilaça, Silva et al. 2014). Namely, they have a 
compromised mitochondrial network in post diauxic shift (PDS) phase, and reduced 
mitochondrial membrane potential, oxygen consumption and cytochrome c oxidase 
activity (COX). These seem to be associated with alterations in sphingolipid levels, 
particularly ceramides and long chain bases, a class of bioactive lipids discussed below 
in section 1.3. 
1.3. Sphingolipids  
 Although lipids were initially seen as being only involved in membrane structure 
and energy metabolism, the discovery that they could modulate cellular responses and 
play a role in signalling changed the way they were seen by biologists and biochemists. 
Sphingolipids are bioactive membrane lipids that play important signaling roles in 
eukaryotes, regulating cellular processes such as apoptosis, senescence, cell growth 
and proliferation (Dickson 2008, Hannun and Obeid 2008). Ceramide, sphingosine and 
sphingosine-1-phosphate (S1P) are the most studied sphingolipids, but their intricate 
metabolism and the several modifications they can endure  gives rise to many different 
forms (see 1.3.1). They are also involved in certain inflammatory processes and many 
pathologies, like cancer (Ogretmen and Hannun 2004).  
Their structure is rather particular - they are composed of a long chain 
sphingoid base (LCB), usually a sphingosine with 18 carbons, which can be amidated 
with a fatty acid to generate ceramide (Figure 2). Ceramide is the precursor of complex 
sphingolipids such as sphingomyelin and glycosphingolipids, which are formed by 
addition of a polar head group (phosphocholine) or a sugar moiety, respectively 
(Malagarie-Cazenave, Andrieu-Abadie et al. 2004). Ceramides can also be 
hydroxylated and exist in saturated and non-saturated forms.  
 
Figure 2 - General structure of ceramide. Ceramide, one of the core sphingolipids in mammals and yeast, is 
composed of sphingosine amidated to a fatty acid of variable length. This sphingolipid is actually a family of more than 
50 species (Hannun and Obeid 2008). 
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1.3.1. Metabolism of sphingolipids in yeast 
The de novo synthesis of LCBs and ceramide 
The de novo synthesis of sphingolipids begins in the ER with the condensation 
of palmitoyl-CoA with serine, in a reaction catalyzed by serine palmitoyltransferase 
(SPT), a membrane associated enzyme, to yield 3-keto-dihydrosphingosine (KDS) 
(Hanada 2003) (Figure 3). This enzyme is encoded by LCB1 and LCB2 in yeast (Lee, 
Lee et al. 2014, Martin, Flandez et al. 2005). Besides Lcb1p and Lcb2p, SPT also 
requires a third subunit, Tsc3p, for optimal activity (Gable, Slife et al. 2000). This step 
represents the only entry point and the first rate-limiting step in this pathway. 
Regulation of SPT controls the rate of sphingolipid synthesis and it can be 
pharmacologically inhibited by myriocin (Wadsworth, Clarke et al. 2013).  
 
Figure 3 - Sphingolipid metabolism in yeast. In Saccharomyces cerevisiae, sphingolipid metabolism is spatially 
divided between the Endoplasmic Reticulum (ER) and the Golgi apparatus (for complex sphingolipids). The first entry 
point is through SPT, and the only exit point is catalyzed by Dpl1p (Rego, Trindade et al. 2012). 
 
In S. cerevisiae KDS is then reduced to dihydrosphingosine (DHS) by Tsc10p, in a 
reaction that requires NADPH as a reducing agent. DHS in turn can be hydroxylated by 
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Sur2p or Syr2p to yield phytosphingosine (PHS). Dihydrosphingosine and 
phytosphingosine are the long chain bases present in yeast and they can be either 
phosphorylated or used to generate ceramide species. Dihydrosphingosine and 
phytosphingosine can be amide linked to a C26 fatty acid to generate dihydroceramide 
(DHC) and phytoceramide (PHC), respectively. This reaction is catalyzed by the 
ceramide synthases Lac1p (longevity assurance gene 1 cognate) and Lag1p (longevity 
assurance gene 1) (Guillas, Kirchman et al. 2001, Schorling, Vallée et al. 2001). Lac1p 
and Lag1p form a heteromeric complex with Lip1p which is required for optimal 
ceramide synthase activity (Vallée and Riezman 2005). Phytoceramide can also be 
generated by the hydroxylation of dihydroceramide catalyzed by Sur2p (Haak, Gable et 
al. 1997).  
At this point, phytoceramide and dihydroceramide can be hydrolyzed back to LCBs 
and a free fatty acid in a reaction catalyzed by Ypc1p or Ydc1p, respectively (Mao 2000, 
Mao, Xu et al. 2000). YDC1 and YPC1 are homologous genes that encode alkaline 
ceramidases in yeast. Ypc1p even has reverse ceramide synthase activity (Mao 2000). 
The LCBs here generated can then be phosphorylated by Lcb4p or Lcb5p to yield their 
phosphorylated analogous, DHS-1-phosphate or PHS-1-phosphate. These species can 
be converted to non lipidic species (hexadecenal or phosphoethanolamine) through the 
only exit point in sphingolipid metabolism in yeast, catalyzed by dihydrosphingosine-1-
phosphate lyase (DPL1p) (Saba, Nara et al. 1997). 
Synthesis and hydrolysis of complex sphingolipids  
Ceramides can also be transported to the Golgi apparatus where they are used for 
the synthesis of complex sphingolipids, through the addition of different polar head 
groups (Dickson 2008). The inositol phosphoryl ceramide synthase, encoded by AUR1, 
adds myo-inositol phosphate to the C1 hydroxyl group of ceramide, to yield inositol 
phosphorylceramide (IPC). Then, IPC can be mannosylated by the transfer of mannose 
from GDP-mannose to form mannose-inositol-phosphorylceramide (MIPC), in a 
reaction catalyzed by the inositol phosphoceramide mannosyl transferase. This 
enzyme can be present in two protein complexes that contain a regulatory subunit 
(Csg2p) and one catalytic subunit (Csg1p or Csh1p). The last and most abundant of 
the complex sphingolipids in yeast, mannose-diinositol-phosphorylceramide (M(IP)2C), 
is generated through the addition of another inositol-phosphate moiety to MIPC, 
catalyzed by the enzyme inositol-phosphotransferase (Ipt1p), (Dickson, Nagiec et al. 
1997). These complex sphingolipids are present in the Golgi apparatus, vacuole and 
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plasma membrane (Hechtberger and Daum 1995), but their function is yet to be 
disclosed. 
The hydrolysis of these complex sphingolipids is catalyzed by inositol 
phosphosphingolipid phospholipase C (Isc1p), the yeast orthologue of mammalian 
neutral sphingomyelinase-2 (Saway, Okamoto et al. 2000). It has phospholipase type C 
activity and cleaves the polar head groups of these lipids, releasing dihydroceramide 
and phytoceramide.  Isc1p is localized in the ER during exponential growth on media 
containing glucose (fermentative metabolism), but then it is translocated to the 
mitochondrial membrane during PDS phase when yeast shift to respiratory growth 
(Vaena de Avalos, Okamoto et al. 2004). This suggests that Isc1p plays a role in 
respiration/mitochondrial function. Consistently, yeast cells lacking Isc1p exhibit 
mitochondrial dysfunctions, a shortened chronological lifespan and hydrogen peroxide 
sensitivity (Almeida, Marques et al. 2008).  
1.3.2. Sphingolipid signaling 
As previously mentioned, different sphingolipids have different functions in the 
regulation of cell metabolism. While ceramides and LCBs are commonly associated 
with apoptosis and cell-cycle arrest, sphingosine-1-phosphate and other 
phosphorylated analogs induce proliferation and cell survival. The cellular effects of 
these lipids in mammals are mostly mediated by protein kinases and phosphatases 
(Figure 4). The interplay between these different types of sphingolipids is rather 
intricate and changes in the activity of enzymes involved in their synthesis or 
degradation may have a huge impact on their levels and ultimately on cell fate (Hannun 
and Obeid 2008). 
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Figure 4 - Cell signaling by sphingolipids in mammals. Ceramides and sphingosine, whose generation is associated 
with different types of stress, induce cell cycle arrest and cell death, while sphingosine-1-phosphate, e.g. generated in 
response to growth factors, has protective and proliferative effects (Hannun and Obeid 2008). 
 
Ceramide Signaling 
 Ceramide occupies a core position in sphingolipid metabolism. It can be produced 
either through the de novo pathway or by the hydrolysis of complex sphingolipids. It is 
also known to activate several protein kinases and phosphatases (Ruvolo 2002) 
(Figure 5). The accumulation of ceramide due to alterations in these pathways has 
been implicated in many diseases. For example, in Farber’s disease a deficiency in 
acid ceramidase leads to an intralysosomal accumulation of ceramide with pathological 
consequences (Park and Schuchman 2006). In what concerns its activity as a second 
messenger, ceramide activates Ser/Thr phosphatases (CAPPs), such as protein 
phosphase 1 (PP1) and protein phosphatase 2A (PP2A) (Chalfant, Szulc et al. 2004), 
enhancing cytotoxic and apoptotic effects. The activation of PP2A is responsible for the 
down-regulation of insulin signaling, and by the dephosphorylation and consequent 
inhibition of the AKT/PKB pathway (Zhout, Summers et al. 1998). Ceramide also 
activates protein kinases, like PKC, and cathepsin D, a protease homolog to yeast 
Pep4p (Heinrich, Neumeyer et al. 2000). Ceramide also affects mitochondrial function: 
when accumulated in this organelle, it inhibits components of the respiratory chain 
favoring the generation of reactive oxygen species (ROS) and ultimately the induction 
of apoptotic events (Siskind 2005). In fact, mitochondrial apoptotic factors can be 
released through ceramide channels in mitochondria. Beclin-1, a tumor suppressor 
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protein that induces autophagosome formation (discussed in section 1.4.3), is also 
activated by ceramide (Scarlatti, Bauvy, et al. 2004). Dephosphorylation and inhibition 
of anti-apoptotic Bcl2 proteins is also induced by ceramide through activation of a 
PP2A (Ruvolo, Deng et al. 1999)  
In yeast, there is a ceramide-activated protein phosphatase containing the 
regulatory subunits Cdc55p and Tpd3p and a catalytic subunit encoded by SIT4 
(Joseph T. Nickels 1996). Sit4p is a type 2A-related Ser/Thr phosphatase, sharing high 
homology with human protein phosphatase 6. It regulates G1/S transition of the mitotic 
cycle, ER to Golgi traffic, cell wall and actin cytoskeleton organization and 
mitochondrial function (Sutton, Immanuel et al. 1991). Sit4p deficiency is known to 
increase chronological lifespan (CLS) as well as hydrogen peroxide resistance 
(Barbosa, Osorio et al. 2011). CLS represents the amount of time a cell survives in 
nutrient depletion conditions, after entering stationary phase (Fabrizio and Longo 2003). 
SIT4 deletion also confers resistance to yeast strains lacking mitochondrial DNA, 
increasing proliferation and mitochondrial membrane potential (Garipler, Mutlu et 
al.2013). Sit4p-deficient cells also show an increased respiratory rate at exponential 
phase, which probably explains the upregulation of antioxidant defenses later on and 
consequent increase in lifespan. However, they fail to grow on respiratory substrates 
such as galactose, ethanol or glycerol (Jablonka, Guzman et al. 2006). In fact, SIT4 
mutants have high glycogen content since they redirect carbohydrate flux to 
glycogenesis. Consistently, sit4Δ cells show a low fermentative capacity (de Assis, 
Zingali et al. 2013). Interestingly, Sit4p can associate with different subunits giving rise 
to complexes involved in distinct pathways. The target of rapamycin complex 1 
(TORC1) down regulates this phosphatase activity through the phosphorylation of 
Tap42p, which then interacts with Sit4p and inhibits it (Di Como and Arndt 1996). Sit4p 
can also associate with the Sit4p associated proteins (SAPs) (Luke, Seta et al. 1996).  
In yeast, ceramide is also involved in the activation of Hog1p, a mitogen-activated 
protein kinase (MAPK) of the high osmotic glycerol pathway (HOG). Hog1p is 
functionally related to mammalian p38 and JNK, both involved in stress-induced 
apoptosis through mitochondrial damage and caspase activation (Hohmann, Krantz et 
al. 2007, Kumar, McLaughlin et al. 2006). Hog1p activation and ceramide have been 
implicated in the reduced lifespan and hydrogen peroxide sensitivity of Isc1p-deficient 
cells (Barbosa, Graça et al. 2012). Consistently, Hog1p phosphorylation increases in 
these mutants by a mechanism dependent of the protein kinase a Sch9p, which acts 
upstream of Hog1p in response to ceramide (Teixeira, Medeiros et al. 2014). 
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Figure 5 - Ceramide activates several protein kinases and phosphatases. Considered to be at the core of 
sphingolipid metabolism, ceramide, produced in response to several stimuli, activates metabolic pathways that 
ultimately result in apoptose in mammalian cells (Ruvolo 2002). 
 
Sphingosine and LCBs signalling 
 Sphingosines are mostly involved in apoptotic events, cell cycle arrest and the 
regulation of actin cytoskeleton and endocytosis (Hannun and Obeid 2008). They are 
known inhibitors of protein kinase C (PKC) (Smith, Merril et al. 2000), mitogen-
activated protein kinases (MAPK) and activators of stress-activated protein kinases 
(SAPK) such as p38 and JNK (Olivier 2002). On the other hand, phosphorylated 
sphingosines like sphingosine-1-phosphate have protective effects in cells, playing 
roles in survival, proliferation. They function in an autocrine way, activating G-protein 
coupled receptors (Strub, Maceyka et al. 2010). In yeast, one of the first observations 
suggesting that LCBs could have a significant role as second messengers was the fact 
that their concentration increase transiently when cells were submitted to heat stress 
(Jenkins, Richards et al. 1997, Dickson 2008). It was later found that these 
sphingolipids are activators of the redundant protein kinases Pkh1p and Pkh2p, 
homologous to mammalian 3-phosphoinositide-dependent protein kinase-1 (PDK1). In 
mammals, PDK1 is involved in the activation of enzymes, including AKT/PKB in the 
response to growth factors and hormones like insulin (Mora, Komander et al. 2004). 
After activation by LCBs, the Pkh1/2p kinases phosphorylate and activate Ypk1/2p, 
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Pkc1p and also Sch9p, the latter in a T570 residue (Dickson 2008). Sch9p is a protein 
kinase belonging to the AGC family that also requires phosphorylation by TORC1 in its 
C-terminal in order to be fully activated (Urban, Soulard et al. 2007). Sch9p, which 
shares high homology to mammalian AKT/Protein kinase B, is involved in the 
regulation of osmostress-responsive genes, mitochondrial function, cell aging, oxidative 
stress and sphingolipid biosynthesis (Pascual-Ahuir and Proft 2007, Lavoie and 
Whiteway 2008, Pan and Shadel 2009, Swinnen, Wilms et al. 2014). In fact, the 
downregulation of Tor1p or Sch9p was shown to increase CLS in yeast (Pan and 
Shadel 2009). Consistently, sch9Δ cells show an upregulation of genes encoding 
subunits of the mitochondrial respiratory chain and an increased respiration rate (Lavoi 
and Whiteway 2008). Sch9p is also involved in the regulation of sphingolipid 
metabolism as recently discovered, by regulating the expression of YPC1 and YDC1 
(Swinnen, Wilms et al. 2014). The deletion of SCH9 leads to an increase in the 
expression of these ceramidases, leading to the turnover of ceramides into LCBs and 
consequently increasing the levels of LCBs and of their phosphorylated forms. Also, 
the downregulation of sphingolipid synthesis by lowering SPT activity is known to 
increase CLS in yeast by reducing TORC1 and, consequently, Sch9p activity (Huang, 
Liu et al. 2012, Liu, Huang et al. 2013). 
1.4. The Target of Rapamycin pathway 
1.4.1. General aspects 
The purification of the macrocyclic lactone rapamycin in the 1970s, and the later 
observation that it was capable of suppressing mammalian cell proliferation, led to the 
identification and characterization of the target of rapamycin (TOR) pathway. TOR is a 
Ser/Thr protein kinase highly conserved in eukaryotic organisms. Indeed, it is present 
in organisms such as S. cerevisiae (where most of the studies have been performed), 
C. elegans, Drosophila and mammals (Raught, Gingras et al. 2001, Rohde, Heitman et 
al. 2001, Schmelzle and Hall 2000). TOR belongs to the family of phosphatidylinositol 
kinase-related kinases (PIKK) and it senses the cell’s nutritional state in order to 
regulate processes such as cellular growth, stress response, autophagy and aging (De 
Virgilio and Loewith 2006, Wullschleger, Loewith et al. 2006). Rapamycin forms a 
complex with FKBP12 that binds and inhibits TOR, mimicking nutrient starvation 
(Rohde, Heitman et al. 2001). Genetic studies in Saccharomyces cerevisiae led to the 
discovery that TOR signaling involves two different complexes, the TOR complex 1 
(TORC1) that is sensitive to rapamycin and the TOR complex 2 (TORC2) that is 
insensitive to rapamycin. These complexes have different functions in cell growth 
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control (Loewith, Jacinto et al. 2002, De Virgilio and Loewith 2006, Wullschleger, 
Loewith et al. 2006) and are conserved in other organisms. In yeast, TORC1 is 
composed of Tor1p or Tor2p, Kog1p, Lst8p and Tco89p, while TORC2 has only Torp2, 
Avo1p, Avo2p, Avo3p, Lst8p and Bit61p. These complexes seem to regulate cell 
growth in different ways: while TORC1 controls temporal aspects of cell growth, like 
ribosome biogenesis, protein biosynthesis and tRNA gene expression, nutrient uptake 
and metabolism, stress responses, mitochondrial function and autophagy, TORC2 
regulates actin cytoskeleton organization and spatial growth (Figure 6). 
 
Figure 6 - The two different TOR complexes in Saccharomyces cerevisiae. TOR signaling is divided in two different 
macromolecular protein complexes, which in yeast are called TORC1 and TORC2. While rapamycin sensitive TORC1 
regulates stress response and temporal aspects of cellular growth, TORC2 controls spatial growth through regulation of 
actin organization (Wullschleger, Loewith et al. 2006). 
TORC1 integrates nutritional cues from nitrogen and carbon sources in order to 
regulate cellular growth (Loewith and Hall 2011). Nutrients are activators of TORC1, 
inducing anabolic processes such as ribosome biogenesis, translation, protein 
synthesis and nutrient import. Nutrient depletion leads to the inactivation of this 
pathway, and the consequent downregulation of transcription and translation (Swinnen, 
Ghillebert et al. 2014). This is mimicked by rapamycin treatment, as cells exit the cell 
cycle and enter into G0 quiescent state. In both cases, the expression of a specific set 
of genes involved in stress response and survival are induced, as well as catabolic 
processes like autophagy (Loewith and Hall 2011).   
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1.4.2. Regulation of mitochondrial function and longevity 
TORC1 is also involved in stress response, mitochondrial function and aging – 
treating mice with rapamycin, even if at later stages, was shown to extend the lifespan 
in mice. In yeast, TORC1 is active during logarithmic phase and inhibits Rim15p, a 
protein kinase required for the activation of the transcription factors Gis1p and 
Msn2p/4p, which upregulate genes associated with stress response and CLS (Wanke, 
Pedruzzi et al. 2005, Wei, Fabrizio et al. 2008). In fact, the deletion of TOR1 increases 
CLS in yeast (Powers III, Kaeberlein et al. 2006, Pan, Schroeder et al. 2011). In early 
stages of growth, Tor1p deficient cells have an increased mitochondrial oxygen 
consumption that increases the production of superoxide radicals. These ROS induce 
an adaptive response that allows cells to maintain ROS levels at low levels in 
stationary phase, increasing the CLS of tor1 mutants (Bonawitz, Chatenay-Lapointe 
et al. 2007). TORC1 regulates lifespan and oxidative stress resistance in part through 
modulation of Sch9p. Indeed, the deletion of SCH9 also improves mitochondrial 
function, oxidative resistance and lifespan in yeast (Pan and Shadel 2009). 
1.4.3. Regulation of autophagy 
Autophagy is a highly regulated cellular process in eukaryotes, conserved from 
yeast to mammals, that plays essential roles in the regulation of normal development 
and cellular homeostasis. In this process, cellular proteins and whole organelles are 
engulfed by cytoplasmic double-membrane vesicles, designated as autophagosomes, 
which then direct the cargo to lysosomes where they are degraded (Klionsky and Emr 
2000). In S. cerevisiae, this degradation step occurs in the vacuole, the yeast 
equivalent to lysosomes in mammalian cells. This process also represents an adaptive 
catabolic response of the cell in order to acquire nutrients and energy from more 
complex molecules, in response to nitrogen starvation or other types of cellular stress 
(Nakatogawa, Suzuki et al. 2009, Yang and Klionsky 2010). Its impairment is known to 
be an underlying cause behind several pathologies in humans, like cancer, immune 
disease and neurodegeneration, and has been implicated in aging (Levine and 
Kroemer 2008). It may lead to the accumulation of unfolded and toxic proteins, among 
other molecules. The autophagic flux seems to be defective in NPC1 cells, due to 
impaired degradation of autophagosomes (Sarkar, Carroll et al. 2013), and the 
restoration of this process may be a therapeutic approach to this problem (Sarkar, 
Maetzel et al. 2014). 
Although initially seen as a non-selective process (macroautophagy), different 
types of autophagy are responsible for the degradation of different organelles in a more 
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selective fashion (Fimia, Kroemer et al. 2013, Kraft, Peter et al. 2010). In 
microautophagy, the lysosomal membrane directly invaginates the cargo to be 
degraded, independently of autophagosome formation. In mitophagy, only damaged or 
aged mitochondria are directed for degradation. This selective type of autophagy is of 
high importance for cells to maintain a good mitochondrial fitness, and represents a 
defense against oxidative stress and aging (Ding and Yin 2013). Pexophagy consists 
on the selective autophagic degradation of peroxisomes, in situations where the 
abundance of this organelle is not necessary anymore (Sakai, Oku et al. 2006). The 
cytoplasm to vacuole targeting (Cvt) pathway, specific to yeast, is responsible for 
delivering hydrolases like aminopeptidase 1 and α-mannosidase to the vacuole, and 
represents the only biosynthetic pathway that uses autophagy machinery (Lynch-Day 
and Klionsky 2010). 
The molecular mechanisms underlying autophagy have been extensively studied in 
yeast where thirty-five autophagy related genes (ATG) have been identified. This 
complex machinery is essential for the autophagic pathways present in yeast: 
macroautophagy, Cvt, pexophagy and mitophagy. Only 15 ATG genes encode the core 
machinery essential for the all subtypes of autophagy (Nakatogawa, Suzuki et al. 2009). 
These are divided into 5 different subgroups, each with a specific function. One of 
these essential genes is ATG8. This gene encodes an ubiquitin-like protein with 
homology to mammalian microtubule-associated protein. It serves as a molecular 
marker for membrane dynamics during autophagy, since it is localized on the isolation 
membranes of autophagosomes (Kirisako, Baba et al. 1999). It is associated to 
phosphatidylethanolamine and it mediates tethering and hemifusion of liposomes in 
response to lipidation, driving the growth of autophagosomes (Nakatogawa, Suzuki et 
al. 2009).  
TORC1 plays a key role in the regulation of autophagy in response to nutritional, 
hormonal and metabolic signals. In yeast, TORC1 negatively regulates 
macroautophagy through the hyperphosphorylation of Atg13p, which is involved in the 
first steps in the activation of this process (Figure 7) (Wullschleger, Loewith et al. 2006, 
Nakatogawa, Suzuki et al. 2009). In starvation like or stress conditions, the inhibition of 
TORC1 leads to the dephosphorylation of Atg13p, allowing its association with the 
Ser/Thr protein kinase Atg1p. This complex then interacts with other core Atg proteins, 
namely Atg17p, Atg29p and Atg31p, recruiting them to the pre-autophagosomal 
structure, necessary for the initiation of autophagy (Nakatogawa, Suzuki et al. 2009). 
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Figure 7 - The role of TORC1 in autophagy regulation in yeast. The inactivation of TORC1 leads to the 
dephosphorilation of Atg13p and consequent association with other Atg proteins, leading to the pre-autophagosomal 
structure organization. 
 
1.4.4. TOR signaling and sphingolipid metabolism 
The TOR pathway is also known to regulate sphingolipid synthesis at several 
levels. TORC1 inhibition stimulates the synthesis of complex sphingolipids downstream 
of SPT, through Npr1p-dependent phosphorylation of Orm1p and Orm2p 
(Shimobayashi, Oppliger et al. 2013). Rapamycin treatment leads to the activation of 
PP2A catalytic subunit Sit4p which in turn activates Npr1p, leading to Orm1/2p 
activation and synthesis of complex sphingolipids. The Orm1/2p also bind to and inhibit 
SPT, modulating the de novo sphingolipid biosynthesis (Breslow, Collins et al. 2010). In 
conditions of sphingolipid depletion (eg., upon treatment with myriocin), TORC2 
activates Ypk1p which in turn phosphorylate and inhibit the Orm proteins, promoting 
SPT activation and sphingolipid synthesis (Roelants, Breslow et al. 2011). 
TORC2 also controls ceramide synthase activity (Aronova, Wedaman et al. 
2008, Dickson 2008). In response to growth signals, TORC2 phosphorylates the 
protein kinase Ypk2p, which if also phosphorylated by Pkh1/2p, activates ceramide 
synthase. This process is also enhanced by LCBs since these are known activators of 
Pkh1/2p. The protein phosphatase calcineurin has the opposite effect by 
downregulating ceramide synthase activity, in response to heat and other stresses 
(Aronova, Wedaman et al. 2008). 
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Recently, it was found that an increase in the levels LCBs in ncr1Δ cells leads to 
the hyperactivation of the Pkh1/2p-Sch9p pathway, resulting in the several 
mitochondrial dysfunctions and reduced lifespan of these mutants (Vilaça, Silva et al. 
2014). TORC1 is a known activator of Sch9p through phosphorylation of its C-terminal 
moiety (Urban, Soulard et al. 2007), and this pathway is involved in aging in response 
to nutrients (Powers III, Kaeberlein et al. 2006, Pan, Schroeder et al. 2011). For this 
reason, we hypothesized genomic deletion of TOR1 could lead to an increase in 
lifespan and resistance to hydrogen peroxide in Ncr1p-deficient cells. Moreover, the 
ceramide activated protein phosphatase Sit4p is activated in ncr1Δ cells, which. is 
correlated with the accumulation of specific ceramide species (Vilaça et al. 
unpublished). The autophagic flux and Pep4p activity are also increased in these cells 
(Vilaça et al. unpublished). However, the role of ceramide, Sit4p and Tor1p in ncr1Δ 
phenotypes is poorly characterized. This work aimed to assess the role of Sit4p in the 
regulation of sphingolipid metabolism, autophagy and vacuolar function in ncr1Δ cells, 
as well as how Tor1p modulates oxidative stress resistance and chronological lifespan 
in this model of NPC1 disease.  
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CHAPTER 3  
MATERIALS AND METHODS 
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3.1. Yeast strains and growth conditions 
Saccharomyces cerevisiae BY4741 was the parental strain of all haploid 
mutants used in this study, which are listed in table 1. Yeast cells were grown 
aerobically at 26ºC in a shaker at 140 rpm, in flasks with a 1:5 ratio of volume/medium, 
to either logarithmic (OD600 = 0.6) or post-diauxic shift (OD600 = 7-10) phase. Growth 
media used were yeast extract peptone dextrose (YPD - 2% (w/v) bacteriological 
peptone, 1% (w/v) yeast extract, 2% (w/v) glucose), yeast extract peptone glycerol 
[YPG -  2% (w/v) bacteriological peptone, 1% (w/v) yeast extract, 3% (w/v) glycerol), 
minimal medium [MM - 0.67% (w/v) yeast nitrogen base without amino acids, 2% (w/v) 
glucose, supplemented with 0.004% (w/v) histidine, 0.008% (w/v) leucine, 0.004% (w/v) 
methionine or 0.004% (w/v) uracil] and synthetic complete drop-out medium [SC - 2% 
(w/v) glucose, 3% (w/v) glycerol or 2% (w/v) galactose and 0.67% (w/v) yeast nitrogen 
base w/o amino acids, 0.14% drop out medium, supplemented with 0.008% (w/v) 
histidine, 0.04% (w/v) leucine, 0.008% (w/v) tryptophan and 0.008% (w/v) uracil].  
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Table 1. Yeast cells used in this work. 
Strain Genotype Source 
BY4741 Mata, his3Δ, leu2Δ, met15Δ, ura3Δ  EUROSCARF 
ncr1Δ::KanMX4 BY4741 ncr1Δ::KanMX4 Vilaça et al., 2014 
ncr1Δ::URA3 BY4741 ncr1Δ::URA3 Vilaça et al., 2014 
sit4Δ BY4741 sit4Δ::HIS3 Vilaça et al., 
unpublished 
ncr1Δsit4Δ BY4741 ncr1Δ::KanMX4 sit4Δ::HIS3  Vilaça et al., 
unpublished 
tor1Δ BY4741 tor1Δ::KanMX4 Teixeira et al., 
2014 
ncr1Δtor1Δ BY4741 ncr1Δ::URA3 tor1Δ::KanMX4 This study 
ydc1Δ BY4741 ypc1Δ::KanMX4 EUROSCARF 
ypc1Δ BY4741 ydc1Δ::KanMX4 EUROSCARF 
lag1Δ BY4741 lag1Δ::KanMX4 EUROSCARF 
ncr1Δypc1Δ BY4741 ncr1Δ::URA3 lag1Δ::KanMX4 Vilaça et al., 
unpublished 
ncr1Δydc1Δ BY4741 ncr1Δ::URA3 ydc1Δ::KanMX4 This study 
ncr1Δlag1Δ BY4741 ncr1Δ::URA3 lag1Δ::KanMX4 This study 
 
3.2. Genomic DNA extraction 
Yeast cells were grown overnight in 10 ml YPD to stationary phase, pelleted 
and resuspended in 100 µl of lysis solution (2% (v/v) triton X-100, 1% (w/v) SDS, 100 
mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA). Cell lysis was performed by adding 
zirconium beads, 50 µl of phenol and 50 µl of chloroform/isomyl alcohol solution (48:1) 
followed by a subsequent 5 min vortexing step. After centrifugation (13,000 rpm, 5 min), 
the aqueous phase was transferred to a new tube containing 100 µl of chloroform and 
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100 µl of TE solution (100 mM Tris, 10 mM EDTA pH 8.0), which was then vortexed 
during 5 min. Afterwards, the aqueous phase was collected again to a new tube to 
which 1 mL of 100% ethanol was added. The mix was left at -20ºC for 5-10 min until 
formation of a precipitate and centrifuged at 14,000 rpm during 5 min. The pellet was 
resuspended in 400 µl of TE buffer and 30 µl of 1 mg/ml RNase A, and incubated at 
37ºC during 7 min. Then 10 µl of 4 M ammonium acetate and 500 µl of 100% ethanol 
were added, and the solution mixed. After centrifugation, the pellet was washed once 
with 200 µl of 70% (v/v) ethanol, centrifuged again, dried and resuspended in 50 µl of 
dH2O. Genomic DNA was then quantified using a Nano-drop spectrophotometer (ND-
1000, Thermo Scientific). 
3.3. Polymerase chain reaction 
Polymerase chain reaction (PCR) was performed with a reaction mix containing 
1X Taq buffer (Promega), 0.2 mM dNTP’s (Thermo Scientific), 0.2 µM forward primer, 
0.2 µM reverse primer, 1.5 mM MgCl2 (Promega) and 1 U Taq Polymerase (Promega), 
to a final volume of 20 µl. The primers used in this study are listed in table 2. For the 
amplification of the KanMX4 cassette used in the disruption of YDC1, the annealing 
temperature was 53ºC and the elongation time 2 min. The KanMX4 cassette also used 
for the disruption of LAG1 was amplified using an annealing temperature of 50ºC and 
an elongation time of 2 min. For the amplification of the HIS3 cassette used in the 
disruption of YDC1, the annealing temperature was 58ºC and the elongation time 1 
minute. For the amplification of the URA3 cassette used in the disruption of NCR1, the 
annealing temperature was 53ºC and the elongation time 2.5 min. All PCR products 
were analyzed by nucleic acid electrophoresis at 100V, using 1% (w/v) agarose gels 
and TAE buffer 1x (40mM Tris, 20mM acetic acid, 1mM EDTA). DNA bands were 
extracted from the gel using the Gel Band Purification Kit (GE Healthcare, Life 
Sciences). 
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Table 2. Primers used in this study 
Primer Sequence 
YDC1_HIS3_Fw 
 
5’TAGTGAATTTTTAAGAAAGTAAGATAAAGAAA
AAAATAACCTCTGACACATGCAGCTCCCGGAG
3’ 
YDC1_HIS3_Rv 
 
5’TATATTTTGAAGATTCAAATGGATGGCACAAA
ATCACTCCCTTCAGTATCATACTGTTC3’ 
YDC1_Amp_Fw 
 
5’TAGTGAATTTTTAAGAAAGTAAGATAAAGAAA
AAAATCAA3’ 
YDC1_Amp_Rv 
 
5’GGAGTGATTTTGTGCCATCCATTTGAATCTTC
AAAATATA3’ 
NCR1_Amp_Fw 5’CCGTGGCTAATGTCACAACA3’ 
NCR1_Amp_Rv 5’TTACGACTGAAGCGTTGACC3’ 
NCR1_Conf_Rv 5’CCAGTGACACCATGAGCATTAG3’ 
Kan_Conf_Rv 5’AATCGAATGCAACCGGC3’ 
YDC1_Conf_Fw 5’CTGATTTTTACTGATCGTAGCCATT3’ 
LAG1_Amp_Fw 5’CGTCATCTTCCATTTGAAATCC3’ 
LAG1_Amp_Rv 5’TCTCGCCAAGACTCCTAGTAAG3’ 
LAG1_Conf_Fw 5’TGACAGATCTCAATGAATCATCG3’ 
 
3.4. Gene deletions and DNA manipulation 
All mutants were generated by homologous recombination and yeast cells 
transformed according to the PEG/Lithium acetate protocol (Gietz and Schiestl 1997), 
as described in 3.5.  
For ncr1Δ::URA3 ydc1Δ::KanMX4 generation, a kanamycin resistance cassette 
containing the flanking regions (40 base pairs) of YDC1 was amplified by PCR, using 
genomic DNA from ydc1Δ::KanMX4 cells and primers YDC1_Amp_Fw and 
YDC1_Amp_Rv (Table 2). BY4741 ncr1Δ::URA3 cells were then transformed with this 
cassette and ncr1Δ::URA3 ydc1Δ::KanMX4 mutants were selected in YPD plates 
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containing 200 ng/ml geneticin (Sigma-Aldrich). For ncr1Δ::URA3 lag1Δ::KanMX4 
generation, a kanamycin resistance cassette containing the flanking regions of LAG1 
(about 300 base pairs) was amplified by PCR, using genomic DNA from 
lag1Δ::KanMX4 cells and primers LAG1_Amp_Fw and LAG1_Amp_Rv. BY4741 
ncr1Δ::URA3 were transformed with this cassette and ncr1Δ::URA3 lag1Δ::KanMX4 
mutants were selected in YPD plates supplemented with 200 ng/ml geneticin. For 
ncr1Δ::URA3 ypc1Δ::KanMX4 ydc1Δ::HIS3 generation, an HIS3 cassette containing 
the flanking regions of YDC1 (40 base pairs) was amplified by PCR from pRS313 
plasmid using primers YDC1_HIS3_Fw and YDC1_HIS3_Rv. BY4741 ncr1Δ::URA3 
ypc1Δ::KanMX4 cells were transformed with this cassette and ncr1Δ::URA3 
ypc1Δ::KanMX4 ydc1Δ::HIS3 mutants were selected in minimal media plates lacking 
histidine. For ncr1Δ::URA3 tor1Δ::KanMX4 generation, an URA3 cassette containing 
the flanking regions of NCR1 (about 300 base pairs) was amplified by PCR, using 
genomic DNA from BY4741 ncr1Δ::URA3 cells and primers NCR1_Amp_Fw and 
NCR1_Amp_Rv. BY4741 tor1Δ::KanMX4 cells were transformed with this cassette and 
ncr1Δ::URA3 tor1Δ::KanMX4 mutants were selected on minimal medium plates lacking 
uracil. The correct insertion of the cassettes was confirmed by, PCR using a forward 
primer complementary to a region outside the recombination area and a reverse primer 
for a region inside the cassette. 
For the β- galactosidase assays, yeast cells were transformed with a plasmid 
expressing the LacZ reporter (YEp357-LacZ) (Swinnen, Ghillebert et al. 2014) under 
the control of endogenous promoters of either YPC1, YDC1, LAC1 or LAG1, and 
selected in minimal medium lacking uracil. For autophagic flux analyses, yeast cells 
were transformed with pRS416-GFP-ATG8 and selected in minimal medium lacking 
uracil (Yorimitso, Zaman et al. 2007). 
3.5. Yeast transformation 
Yeast cells were grown overnight in YPD (20 ml, OD600 = 0.8), harvested at 
4,000 rpm for 5 min, washed and resuspended in 100 µl of dH2O. 50 µl of cells were 
used as negative control or for transformation. Afterwards, 240 µl of 50% (w/v) 
polyethylene glycol 3350 (PEG), 36 µl of 1 M lithium acetate and 25 µl of 5 mg/ml 
single stranded carrier DNA were added to the cell mix. An amount equivalent to 100 
ng of plasmid DNA or 500 ng of the disruption cassette was added. For gene deletion 
the cell mix was initially incubated at 26ºC for 30 minutes and then another half hour at 
42ºC, whereas for plasmid transformation only the latter step was carried out. After 
incubation, cells were pelleted, washed with dH2O and plated on selective medium. 
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3.6. β galactosidase assay 
Cells expressing LacZ reporters were grown in SC glucose medium lacking 
uracil to exponential phase (20 ml, OD600=0.6). Cells were harvested by centrifugation 
(4,000 rpm, 5 min) and lysed in 100 µl of breaking buffer (100 mM Tris-HCl, 10% (v/v) 
glycerol) supplemented with a mix of protease inhibitors (Complete, Mini, EDTA-free 
Protease Cocktail Inhibitor Tablets; Boheringer, Manheim). Cell disruption was done 
using zirconium beads and by vortexing five times for one minute, with one minute 
intervals on ice. Cellular extracts were then centrifuged (14,000 rpm, 15 min) at 4º C 
and the supernatant was collected. Protein levels were quantified by the Lowry assay, 
using bovine serum albumin as a standard. A volume equivalent to 70 µg of protein 
was then diluted in Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM 
MgSO4, 50 mM β-mercaptoethanol) to a final volume of 800 µl. The mix was briefly 
incubated at 30ºC and reactions initiated by adding 200 µl of 4 mg/ml 2-nitrophenyl-β-
D-galactopyramidose (Sigma-Aldrich) for the appropriate time, until formation of a 
yellow color. Reactions were stopped using 400 µl of 1 M Na2CO3, and OD420 was 
measured. 
3.7. Pep4 activity 
Pep4 activity was determined by measuring the release of tyrosine containing 
acid-soluble peptides from acid denatured hemoglobin (Jones 1990). Cultures were 
grown overnight in YPD medium and harvested in exponential (55 ml, OD600 = 0.6) or 
PDS (OD600 = 6-10) phase. Cells were lysed in 100 µl Tris-HCl (pH 7.6) as previously 
described and protein levels quantified using the Lowry assay. A volume equivalent to 
250 µg of protein was diluted in Tris-HCl to a final volume of 50 µl. Extracts were then 
incubated at 37º C with 1 ml of Hemoglobin-Glycine solution (2% (w/v) hemoglobin - 
0.2 M glycine pH 3.2, in a 1:1 ratio) for 0 and 30 min, and the reactions stopped by 
adding 100 µl of 1 N perchloric acid on ice. Samples were centrifuged (30 min, 13,000 
rpm), and 70 µl of supernatant were added to 700 µl of a solution of 2% (w/v) Na2CO3 : 
1% (w/v) CuSO4 : 2% (w/v) Na
+K+ Tartarate (100:1:1 ratio). Afterwards, 70 µl of 0.5 M 
NaOH were added to the samples and following 10 min of incubation, 70 µl of Folin 
reagent (Merck) diluted 1:1 in dH2O were added. The OD750 was measured and results 
were expressed in µg Tyr.min-1. 
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3.8 Oxidative stress resistance assay and 
chronological lifespan 
For oxidative stress resistance, yeast cells were grown in SC-glucose medium 
to exponential phase (OD600=0.6) and then treated with 1.5 mM H2O2 (Merck) for one 
hour. Afterwards, OD600 was measured and cells were diluted, plated on YPD medium 
containing 1.5% (w/v) agar, and grown for 3 days at 26ºC. Colonies were counted and 
cell viability was expressed as the percentage of colony forming units relative to 
untreated cells. To assess the effect of rapamycin on H2O2 resistance, cells were 
grown to OD600=0.3 and pre-treated with 200 ng/ml rapamycin [Sigma-Aldrich; 
dissolved in dimethyl sulfoxide (DMSO)] or equal volume of the vehicle for three hours. 
For chronological lifespan, overnight cultures were diluted in SC-glucose 
medium to an OD600 = 0.6, then grown for 24 h (to post-diauxic shift phase, t = 0) and 
kept in growth media overtime at 26ºC. Cells were subjected to standard dilutions and 
plated on YPD medium supplemented with 1.5% (w/v) agar. Viability was expressed as 
the percentage of colony forming units when compared to t = 0. 
3.9. Autophagic flux analyses and Western 
Blotting 
For the autophagic flux assay, cells expressing pRS416-GFP-ATG8 were grown 
in SC-glucose medium lacking uracil to exponential phase and treated with either 200 
ng/ml rapamycin (Sigma-Aldrich) or equal volume of vehicle (Sigma-Aldrich) for 3h. 
Cells were lysed in 100 µl of phosphate buffer (50 mM KH2PO4, 0.1 mM EDTA pH 7.0) 
supplemented with protease inhibitors and protein concentration was quantified by the 
Lowry assay. A volume equivalent to 30 µg was then diluted in an equal volume of 
sample buffer 2X (4% (w/v) SDS, 20% (v/v) glycerol, 10% (v/v) 2-mercaptoethanol, 
0.004% (w/v) bromophenol blue, 0.125 M Tris HCl). Samples were then heated for 5 
min at 95ºC. Proteins were separated by SDS-PAGE in a 10% SDS-polyacrylamide gel 
and transferred onto a nitrocellulose membrane (GE Healthcare, Life Sciences). The 
membrane was then blocked for 2 h in 5% (w/v) non-fat dry milk in TTBS (20 mM Tris, 
140 mM NaCl, 0.05% (v/v) Tween-20, pH 7.6) and incubated overnight at 4ºC with 
mouse anti-GFP antibody (Roche, Basel, Switzerland) diluted 1:5000 in TTBS 
containing 5% milk, or mouse anti-Pgk (1 : 50000). After washing with TTBS, the 
membrane was incubated for 1 h with goat anti-mouse IgG-peroxidase antibody 
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(Invitrogen) diluted 1:10000 in TTBS containing 5% milk. Immunodetection was 
performed by chemiluminescence using WesterBrighttm ECL reagent (Advansta) and 
exposing the membranes to an X-ray film. 
For stripping, membranes were washed in TTBS and incubated with stripping 
buffer (62.5 mM Tris-HCl, pH 6.8, 2% (w/v) SDS, 10 mM 2-mercaptoethanol) for 30 min 
at 50ºC. Membranes where washed again for complete removal of β-mercaptoethanol. 
3.10. Growth in glycerol plates 
 In order to evaluate respiratory capacity, yeast cells were grown overnight in 
SC-glucose to exponential phase (OD600= 0.6). Cultures were then diluted to an 
OD600=0.1 and fivefold serial dilutions were plated on SC-glucose and SC-glycerol 
medium containing 1.5 % agar (w/v). Cells were grown for 3-5 days at 26ºC. 
3.11. Statistical analyses 
 Results were analyzed using GraphPad Prism software v6.02, and by mean 
and standard deviation of at least three independent experiments. Values were 
compared by one-way ANOVA with Bonferroni test. 
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CHAPTER 4 
RESULTS 
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4.1. Sphingolipid metabolism in ncr1Δ cells 
4.1.1. Sit4p regulates sphingolipid metabolism in the yeast 
model of NPC1 
 Aiming to characterize how sphingolipid metabolism is affected in ncr1Δ cells 
and the role of Sit4p in those changes, the expression of genes encoding for ceramide 
synthases (LAC1 and LAG1) or ceramidases (YPC1 and YDC1) was measured in 
BY4741, ncr1Δ, sit4Δ and ncr1Δsit4Δ cells transformed with a LacZ reporter under the 
control of the respective promoters. The analysis of β-galactosidase activity showed 
that the expression of the genes encoding for the ceramide synthases Lac1p and 
Lag1p increased in ncr1Δ cells when compared to parental cells (Figure 8). This 
increase was mostly noted for LAG1, which presented a 10-fold upregulation while 
LAC1 expression only increased 2-fold. Importantly, the deletion of SIT4 in ncr1Δ cells 
decreased the expression of these genes to levels similar to those observed in parental 
cells. 
 
Figure 8 - Expression of ceramide synthase genes are increased in ncr1Δ cells by a Sit4p-dependent 
mechanism. S. cerevisiae BY4741, ncr1Δ, sit4Δ and ncr1Δsit4Δ cells carrying LacZ reporter fusions with the promoters 
of LAG1 or LAC1 in the multicopy plasmid YEp357 were grown to log phase (OD600=0.6) in SC-medium lacking uracil. -
Galactosidase activity was measured spectophotometrically, as described in methods. Results are mean ± SD values of 
at least three independent experiments. ***p<0.0001 
The expression of the genes encoding for the ceramidases Ypc1p and Ydc1p 
also increased in Ncr1p deficient cells (Figure 9), although not so significantly as for 
LAG1 gene. Indeed, YPC1 and YDC1 were upregulated 5- and 4-fold, respectively, in 
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ncr1Δ cells when compared to parental cells. The deletion of SIT4 in ncr1Δ cells also 
suppressed these changes as β-galactosidase activity in ncr1Δsit4Δ double mutants 
was similar or even lower to wild type levels. 
 
Figure 9 - Expression of ceramidase genes are increased in ncr1Δ cells by a Sit4p-dependent mechanism. S. 
cerevisiae BY4741, ncr1Δ, sit4Δ and ncr1Δsit4Δ cells carrying LacZ reporter fusions with the promoters of YPC1 or 
YDC1 in the multicopy plasmid YEp357 were grown to log phase (OD600=0.6) in SC-medium lacking uracil. B-
Galactosidase activity was measured spectophotometrically, as described in the methods section. Results are mean ± 
SD values of at least three independent experiments. *p<0.05, ***p<0.0001 
Taken together, these results suggest an increase in the expression of both 
ceramidases and ceramide synthases in ncr1Δ cells, in a Sit4p dependent manner. 
This indicates that sphingolipid dynamics are altered in these cells. A higher activity of 
these enzymes may very well be the underlying cause behind the altered sphingolipid 
levels in the yeast model of NPC1. 
4.1.2. Modulation of sphingolipid metabolism in ncr1Δ cells 
The upregulation of ceramide synthase and ceramidase genes prompted us to 
investigate the role of these enzymes in the phenotypes presented by ncr1Δ cells. For 
that, we deleted those genes in Ncr1p deficient cells and assessed its impact on 
mitochondrial function by assessing its capacity to grow on media containing glycerol 
(non-fermentable carbon source). We first deleted LAG1, since the expression of this 
gene presented the most notorious increase in ncr1Δ cells and, therefore, Lag1p could 
have a major contribution to the accumulation of ceramides in this mutant (Vilaça et al. 
unpublished). Also, the deletion of this gene is known to increase chronological life-
span in yeast cells, which is closely related to mitochondrial function (D'mello, 
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Childress et al. 1994). To monitor respiratory capacity, BY4741, ncr1Δ, lag1Δ and 
ncr1Δlag1Δ cells were grown in SC-glucose medium to exponential phase, diluted to 
and OD600=0.1 and fivefold dilutions were plated on SC-Glucose and SC-Glycerol 
plates. BY4741 and lag1Δ cells, but not ncr1Δ cells, were able to grow in glycerol 
plates (Figure 10). However, ncr1Δlag1Δ cells did not grown in this medium, 
suggesting that the deletion of LAG1 does not restore the respiratory capacity in cells 
lacking Ncr1p. Similar results were obtained with ncr1Δydc1Δ cells (Figure 11) as well 
as ncr1Δydc1Δypc1Δ triple mutants (data not shown). 
 
Figure 10 - Deletion of LAG1 in ncr1Δ cells does not restore mitochondrial function. Yeast cells were grown 
overnight to log phase in SC-glucose medium, then diluted to an OD600=0.1 and fivefold serial dilutions were spotted in 
SC-glucose or SC-glycerol plates. 
 
Figure 11 - Deletion of YDC1 in ncr1Δ cells does not restore mitochondrial function. Yeast cells were grown 
overnight to log phase in SC-glucose medium, then diluted to an OD600=0.1 and fivefold serial dilutions were spotted in 
SC-glucose or SC-glycerol plates. 
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Myriocin is an inhibitor of serine-palmitoyl transferase, an enzyme that catalyzes 
the first step in the de novo synthesis of sphingolipids (Miyake, Kozutsumi et al. 1995). 
It was recently reported that myriocin was capable of increasing yeast chronological 
lifespan, through the inhibition of sphingolipid synthesis and consequent down 
regulation of the Pkh1/2p-Sch9p pathway (Huang, Liu et al. 2012, Liu, Huang et al. 
2013). This prompted us to investigate the effect of myriocin on the mitochondrial 
function of ncr1Δ cells. For that, cells were grown on SC-glucose and SC-glycerol 
plates supplemented with 350 ng/ml myriocin. The results show that the inhibition of 
SPT and consequent lowering of sphingolipid burden in ncr1Δ cells was not capable of 
restoring mitochondrial function (Figure 12). 
 
Figure 12 - Inhibition of SPT does not improve the mitochondrial function of ncr1Δ cells. Yeast cells were grown 
overnight to log phase in SC-glucose medium, then diluted to an OD600=0.1 and fivefold serial dilutions were spotted in 
SC-glucose or SC-glycerol plates containing 350 ng/ml myriocin or equal volume of ethanol (vehicle). 
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4.2. Involvement of Sit4p in autophagy and 
Pep4 activity in the yeast model of NPC1 
4.2.1. The deletion of SIT4 in ncr1Δ cells restores the 
autophagic flux 
 In mammals, NPC1 deficient cells show increased basal autophagy as 
evidenced by the increased levels of LC3-II (Pacheco, Kunkel et al. 2007). However, 
there is an impaired degradation of autophagosomes (Sarkar, Carroll et al. 2013). In 
yeast, ncr1Δ cells also present an increased basal autophagic flux as well as an 
increase in the activity of the vacuolar protease Pep4p (Vilaça et al. unpublished). To 
investigate whether Sit4p is implicated in the modulation of autophagy in ncr1Δ cells, 
we analysed the processing of GFP-Atg8p in basal conditions and upon treatment with 
rapamycin to induce autophagy  (Yorimitsu, Zaman et al. 2007). Atg8p is an ubiquitin 
like protein, homolog to mammalian LC3-II, and involved in the formation of 
autophagosomes. When autophagy is induced, GFP-Atg8p recruited to the 
phagophore and lipidated with phosphatidylethanolamine to drive autophagosome 
biogenesis (Kirisako et al., 1999). It is then delivered to the vacuole where Atg8p is 
degraded by resident vacuolar hydrolases. However, the GFP moiety is relatively 
resistant to proteolysis, whereby the appearance of free GFP signal is indicative of 
autophagic flux induction (Shintani and Klionsky, 2004). As previously observed, the 
basal autophagic flux was increased in ncr1Δ cells when compared to parental or sit4Δ 
cells (Figure 13). Treating cells with rapamycin was capable of inducing the autophagic 
flux in all strains, including ncr1Δ cells. In the double mutant ncr1Δsit4Δ, the 
autophagic flux was restored to levels similar to those observed for sit4Δ cells. This 
result implicates Sit4p in the increased autophagic flux of Ncr1p deficient cells.  
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Figure 13 - Analysis of the autophagic flux in BY4741, ncr1Δ, sit4Δ and ncr1Δsit4 cells.  Cells carrying pRS416-
GFP-Atg8 were grown to exponential phase in SC-Glucose medium without uracil and treated with 200 ng/ml rapamycin 
(Rap) or equal volume of DMSO (vehicle) for three hours. Protein extracts were analyzed by western blot using an anti 
GFP antibody. One out of three independent experiments is shown. 
 
4.2.2. The deletion of SIT4 in ncr1Δ cells restores normal Pep4p 
activity 
 Pep4p is the major vacuole protease in yeast (Woolford, Daniels et al. 1986). It 
is responsible for the posttranslational activation of percursors of vacuolar hydrolazes 
and degradation of cargo during autophagy. Cathepsin D, a closely related protease in 
mammals, is increased in NPC cells (German, Liang et al. 2002), a feature found to be 
conserved in the yeast model for this disease (Vilaça et al. unpublished). To assess the  
involvement of Sit4p in the deregulation of Pep4 in ncr1Δ cells, we measured its activity 
in ncr1Δ, sit4Δ and ncr1Δsit4Δ cells grown to exponential and PDS phase.  
In all strains, Pep4p activity increased during growth from exponential to PDS 
phase (Figure 14). As previously reported, ncr1Δ cells presented an increased Pep4p 
activity when compared to parental cells, particularly at the exponential phase (3-fold). 
Notably, the deletion of SIT4 in ncr1Δ cells decreased significantly Pep4p activity to the 
levels observed in parental and sit4Δ cells. The overall results implicate the ceramide 
activated protein phosphatase Sit4p in basal autophagy induction and Pep4p activation 
in Ncr1p deficient cells.  
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Figure 14 - Pep4p activity is increased in ncr1Δ cells by a Sit4p-dependent mechanism.  Yeast cells were grown 
on YPD medium to exponential (log) or post-diauxic shift (PDS) phase. Pep4p activity was measured 
spectrophometrically as described in methods. Results are mean ± SD values of at least three independent experiments. 
*p<0.05, **p<0.01, ***p<0.001 
 
4.3. Role of Tor1p in the oxidative stress 
resistance and chronological lifespan of 
ncr1 cells. 
4.3.1. TORC1 downregulation suppresses the hydrogen 
peroxide sensitivity of ncr1Δ cells 
 TORC1 is a Ser/Thr protein kinase in yeast and conserved in many other 
eukaryotic organisms. It senses nutritional cues and regulates cellular growth as well 
as anabolic processes, like protein synthesis, ribosome biogenesis, among others 
(Loewith and Hall 2011). It also regulates transcription factors involved in the 
expression of stress response genes, like Gis1p and Msn2/4p, through the protein 
kinase Rim15p (Wanke, Pedruzzi et al. 2005, Wei, Fabrizio et al. 2008). In fact, the 
modulation of this pathway is known to increase longevity not only in mammals but also 
in yeast (Bonawitz, Chatenay-Lapointe et al. 2007, Pan, Schroeder et al. 2011, Pan 
and Shadel 2009). In the regulation of aging and mitochondrial function in yeast, 
TORC1 functions upstream of Sch9p, activating it through the phosphorylation of its C-
terminal (Urban, Soulard et al. 2007). It also regulates Sit4p, by phosphorylating 
Tip41p/Tap42p which then interact with Sit4p and inhibit its function (Di Como and 
Arndt 1996). TOR is also an established inhibitor of autophagy (Wullschleger, Loewith 
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et al. 2006, Nakatogawa, Suzuki et al. 2009), which is deregulated in ncr1Δ cells. 
Moreover, previous studies implicate Sch9p in the mitochondrial dysfunction, oxidative 
stress sensitivity and shortened lifespan of ncr1Δ cells (Vilaça et al., 2014). Since 
TORC1 is required for full activation of Sch9p (Urban, Soulard et al. 2007), we 
assessed how TORC1 downregulation affects ncr1Δ phenotypes. 
First, we analysed hydrogen peroxide resistance in BY4741, ncr1Δ, tor1Δ and 
ncr1Δtor1Δ cells, as well as in BY4741 and ncr1Δ cells treated with rapamycin for the 
pharmacological inhibition of TORC1. The results show that, as previously reported 
(Vilaça, Silva et al. 2014), ncr1Δ cells were more sensitive to hydrogen peroxide than 
parental cells (Figure 15). Notably, the deletion of TOR1 in ncr1Δ cells increased 
cellular viability (4-fold) to the levels observed in parental and tor1Δ cells. Consistently, 
the pharmacological inhibition of TORC1 using rapamycin had a protective effect 
similar to the observed upon TOR1 deletion. However, the oxidative stress resistance 
of ncr1Δ cells treated with rapamycin was significantly lower to that of parental cells 
treated with this drug.  
 
 
Figure 15 - Deletion of TOR1 or rapamycin treatment increases hydrogen peroxide resistance in ncr1Δ cells.  (A) 
Cells were grown in SC-Glucose medium to earl-exponential (OD600=0.3), treated with 200 ng/ml rapamycin or equal 
volume of DMSO (vehicle) for three hours, and then for one hour with 1.5 mM H2O2. (B) Cells were grown to exponential 
phase (OD=0.6) and treated with 1.5 mM H2O2 for one hour. Results are mean ± SD values of at least three 
independent experiments. **p<0.01, ****p<0.0001 
 
4.3.2. Deletion of TOR1 restores chronological lifespan in ncr1Δ 
cells 
 Yeast is a well established model for studying both replicative and chronological 
aging (Longo and Shadel 2012). In yeast, CLS represents the time a nondividing cell 
survives in stationary phase. Nutrient sensing pathways, including the Tor1p-Sch9p 
40 FCUP ICBAS 
Sphingolipid metabolism, Sit4p and TORC1 in the yeast model of Niemann-Pick type C1 disease 
 
pathway, are known to be involved in the regulation of yeast lifespan through the 
modulation of mitochondrial function. In fact, the downregulation of the TOR pathway in 
yeast has been reported to increase CLS (Bonawitz, Chatenay-Lapointe et al. 2007, 
Pan and Shadel 2009, Pan, Schroeder et al. 2011). 
 Previously, it was reported that the yeast model of NPC1 presents a reduced 
CLS when compared to parental cells (Vilaça et al, 2014). The deletion of TOR1 in 
ncr1Δ cells suppresses mitochondrial dysfunction (Vilaça et al. unpublished) and the 
oxidative stress sensitivity (this study) of this mutant. To investigate the role of Tor1p in 
aging of ncr1Δ cells, we assessed the CLS of BY4741, ncr1Δ, tor1Δ and ncr1Δtor1Δ 
cells. Consistent with published data, CLS increased in tor1Δ cells comparing with 
parental cells. Importantly, the results show that TOR1 deletion also increased life span 
in Ncr1p deficient cells (Figure 16). In fact, the double mutant cells had a lifespan 
similar to the observed in tor1Δ cells and, therefore, higher to that of parental cells. 
This result implicate TORC1 in the premature aging of ncr1Δ cells.  
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Figure 16 - Deletion of TOR1 in ncr1Δ cells increases chronological lifespan.  Overnight cultures were diluted to an 
OD600=0.6 in SC-glucose, grown for 24 hours until PDS phase and then kept in the medium overtime. Cellular viability 
was expressed as the percentage of colony forming units, in relation to t0. Results are mean ± SD values of at least 
three independent experiments. 
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DISCUSSION 
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Niemann-Pick type C is an autosomal hereditary disease, characterized by an 
acute accumulation of low density lipoprotein derived cholesterol, in late 
endosomes/lysosomes. This affects both the central nervous system and systemic 
organs like spleen and liver in patients with a wide range of ages. Cells of these 
patients also accumulate other classes of lipids, such as phospholipids, gangliosides 
and sphingolipids (Vanier 2010). Sphingolipids are bioactive compounds that function 
as signaling molecules, besides their structural roles in biological membranes. They 
regulate apoptosis, cell senescence but also proliferation and cell cycle (Hannun and 
Obeid 2008). NPC1 cells accumulate sphingosine, which causes alterations in calcium 
homeostasis and in the storage of other lipids (Loyd, Morgan et al. 2008). NPC1 has an 
orthologue in yeast, namely Ncr1p, a protein localized in the yeast vacuole, the 
equivalent to lysosomes in mammalian cells (Zhang, Ren et al. 2004). The deletion of 
NCR1 in yeast also causes the accumulation of LCBs that activate the Pkh1/2p-Sch9p 
pathway, leading to mitochondrial dysfunction, oxidative stress sensitivity and a 
decrease in lifespan (Vilaça, et al 2014). 
Our lab has previously shown that specific ceramide species, in particular C14- 
to C20-phytoceramides, also accumulate in ncr1Δ cells in both exponential and post 
diauxic shift phase (Vilaça et al, unpublished). A Toxoplasma model of NPC1, where 
the gene encoding for TgNCR1 is deleted, also shows increased sphingolipid levels, 
particularly ceramides (Lige, Romano et al. 2011). Increased ceramide levels can 
induce cell death in yeast (Nagiec, Nagiec et al. 1997). Ceramides are activators of 
Sit4p, a protein phosphatase related to type 2A family of protein phosphatases, 
causing mitochondrial dysfunction and a shortened lifespan (Barbosa, Osorio et al. 
2011). This complex consists also of Cdc55p and Tpd3p (Joseph T. Nickels 1996). 
Notably, Sit4p is activated in ncr1Δ cells and SIT4 deletion leads to restoration of 
mitochondrial function and chronological lifespan in Ncr1p-deficient cells (Vilaça et al. 
unpublished). These results suggest that sphingolipid metabolism is altered in these 
cells.  
In this study, we used a β-galactosidase reporter gene to analyze promoter 
activity of genes encoding for ceramide synthases (LAC1 and LAG1) and ceramidases 
(YPC1 and YDC1). Our results indicate that all these genes are upregulated in ncr1Δ 
cells, with LAG1 having the most noticeable increase (10-fold). For all cases, Sit4p was 
apparently involved since SIT4 deletion abolished the induction of these genes in 
ncr1Δ cells. These results suggest that Sit4p, besides being activated by ceramide, 
regulates the metabolism of sphingolipids. This is supported by a recent study showing 
that SIT4 deletion leads to a downregulation of ceramide synthesis (Woodacre, Lone et 
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al. 2013). Whether changes in the expression of the ceramide synthases and 
ceramidase genes are associated with a higher activity of these enzymes remains to 
be determined.  
The changes in the sphingolipid dynamics in ncr1Δ cells led us to postulate that 
an increase in the synthesis of ceramide species by ceramide synthases, leading to 
Sit4p activation, and its turnover by ceramidases, ultimately leading to LCBs 
accumulation and Pkh1/2p activation, may contribute to ncr1Δ phenotypes (Figure 17). 
Indeed, changes in sphingolipid metabolism are known to affect oxidative stress and 
lifespan in yeast (Jiang, Kirchman et al. 2004, Barbosa, Osorio et al. 2011). Genes 
involved in sphingolipid metabolism have been shown to modulate of lifespan, namely 
LAG1, since its deletion appears to extend CLS in yeast (D'mello, Childress et al. 
1994). However, downregulation of these enzymes did not improve the mitochondrial 
function in ncr1Δ cells. Since the accumulation of both LCBs and ceramides can be 
toxic to cells, the deletion of ceramide synthase and ceramidase genes may not be 
sufficient to suppress ncr1Δ phenotypes as it may further increase LCBs and ceramide 
levels, respectively. Regarding ceramide, its accumulation may also be due to a higher 
activity of Isc1p, an orthologue of mammalian sphingomyelinase that catalyzes the 
degradation of inositol phosphoinositolsphingolipids, releasing ceramide (Saway, 
Okamoto et al. 2000). More studies are required to assess the role of Isc1p in ncr1Δ 
phenotypes.  
The levels of LCBs are a balance between its formation (by de novo 
biosynthesis or through the action of ceramidases) and its phosphorylation mediated by 
LCB kinases such as Lcb4p, the major kinase responsible for the synthesis of LCB-1-
phosphates in yeast (Nagiec, Skrzypek et al. 1998). This protein is activated by 
phosphorylation, a process regulated by the sterol composition (Nagiec, Skrzypek et al. 
1998). Since Ncr1p deficient cells present alterations in ergosterol homeostasis (Vilaça 
et al, 2014), Lcb4p activity may be compromised in these cells. Also, LCB-1-
phosphates are known to counteract the pro-apoptotic effects of sphingosine and 
ceramide (Strub, Maceyka et al. 2010), although its accumulation can also be toxic in 
yeast (Kim, Fyrst et al. 2000). Thus, the overexpression of Lcb4p may have protective 
effects in ncr1Δ cells, by decreasing the “pool” of toxic LCBs. Whether Lcb4p is 
deregulated in this mutant remain to be clarified. 
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Figure 17 - Interplay between ceramide species and LCBs in yeast. In ncr1Δ cells, both LCBs and ceramide species 
may induce mitochondrial dysfunctions, through activation of the Pkh1/2p-Sch9p pathway and Sit4p, respectively. 
The modulation of cell signaling pathways that regulate overall sphingolipid 
metabolism may be required to properly restore the sphingolipid rheostat and 
mitochondrial function in ncr1Δ cells. Ceramide synthases are regulated by TORC2 
and calcineurin (Dickson 2008). Sensing growth signals, TORC2 phosphorylates the 
AGC kinase Ypk2p (Kamada, Fujioka et al. 2005), which then activates ceramide 
synthase (Aronova, Wedaman et al. 2008). Ypk2p activation also requires its 
phosphorylation by Pkh1/2p (Dickson 2008), which is known to be activated in ncr1Δ 
cells (Vilaça et al, 2014). It would be interesting in the future to analyze the 
phosphorylation status of Ypk2p and its role in the modulation of ceramide synthesis in 
ncr1Δ cells.  
In mammals, sphingolipids also play a role in autophagy regulation (Li, Li et al. 
2014). This is a conserved process in eukaryotic cells used to recycle damaged 
organelles or long-lived proteins (Klionsky and Emr 2000). Ceramide for example 
induces macroautophagy via upregulation of Beclin 1, an homolog to yeast Atg6p, and 
inhibition of protein kinase B (Scarlatti, Bauvy et al. 2004). Basal autophagy, as well as 
lysosomal proteases like cathepsin D, are known to be increased in NPC1 cells 
(Amritraj, Wang et al. 2013, German, Liang et al. 2002). However, Cathepsin B activity 
is lower and autolysosome turnover is impaired due to lipid accumulation (Elrick, Yu et 
al. 2012). In ncr1Δ cells, both autophagic flux and Pep4p activity are increased (Vilaça 
et al. unpublished). However, the mechanisms underlying autophagy induction were 
still elusive. Our data implicate Sit4p in the increased basal autophagic flux in ncr1Δ 
cells. Consistently, SIT4 deletion in ncr1Δ cells also diminished Pep4p activity in cells 
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grown to both exponential and PDS phase. However, there is still a lot to uncover 
regarding the mechanisms involved in the deregulation of autophagy in these mutants. 
It is known that subunits of protein phosphatases type 2A regulate positively the 
transcription of autophagy related genes, like ATG14, through modulation of 
transcription factors like Gln3p (Cebollero and Reggiori 2009). This may explain the 
downregulation of autophagic flux in cells lacking Sit4p, the catalytic subunit of PP2A in 
yeast. Myriocin is also a known inducer of autophagy through the down regulation of 
TORC1 activity (Liu, Huang et al. 2013) and in mammalian cells, autophagy induction 
leads to an accumulation of lipids in the lysosomes (Elrick, Liu et al. 2012). Thus, the 
treatment with myriocin may not have a beneficial effect by further enhancing the 
autophagic flux and lipid accumulation. 
TORC1 is a negative regulator of autophagy (Wullschleger, Loewith et al. 2006, 
Nakatogawa, Suzuki et al. 2009) and of Sit4p (Di Como and Arndt 1996), and an 
activator of Sch9p (Urban, Soulard et al. 2007). In yeast, this large protein complex 
functions as a controller of cellular growth, stress response and ribosome biogenesis 
(Wullschleger, Loewith et al. 2006). TOR is also an established key player in the aging 
process in several organisms. Treatment of mice with rapamycin, a known inhibitor of 
the TORC1 pathway, extends lifespan even when the animals are treated at later 
stages in life (Harrison, Strong et al. 2009).  In Saccharomyces cerevisiae, deletion of 
TOR1 leads to a higher chronological lifespan due to an upregulation of genes 
encoding mitochondrial proteins, and increased respiration rate (Bonawitz, Chatenay-
Lapointe et al. 2007). These mutants also induce an adaptive response to an increase 
of ROS production during growth at the exponential phase that leads to an enhanced 
lifespan in stationary phase (Pan, Schroeder et al. 2011). TORC1 downregulation leads 
to activation of the protein kinase Rim15p, which promotes the translocation of the 
transcription factors Msn2/4p and Gis1p into the nucleus. As consequence, the 
expression of stress response genes increases and cells accumulate trehalose and 
glycogen, increasing cell survival under nutrient starvation and during aging in yeast 
(Wullschleger, Loewith et al. 2006).  
In this study, we analyzed hydrogen peroxide resistance of ncr1Δ cells deleted 
for TOR1 or treated with rapamycin. Our results show that both suppressed the 
sensitivity of ncr1Δ cells to hydrogen peroxide. Consistent with this, we also observed a 
significant increase in chronological lifespan in ncr1Δtor1Δ cells. The mitochondrial 
function is also restored in these double mutants, as shown by their capacity to grow 
on non-fermentable substrates and by the increase of oxygen consumption rate to 
parental levels (Vilaça et al, unpublished). The overall data implicate the TOR1 
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pathway in the defective stress response and mitochondrial function of ncr1Δ cells, 
leading to a shortened lifespan. The mechanism underlying the protective effect of 
TOR1 deletion remains to be elucidated. TORC1 signaling is, in part, mediated by 
phosphorylation of Sch9p in its C-terminal domain (Urban, Soulard et al. 2007). 
Previous studies have shown that Sch9p-Thr570 phosphorylation in its activation loop 
increases in ncr1Δ cells due to activation of Pkh1p in response to the accumulation of 
LCBs (Vilaça et al, 2014). Thus, it could be that a higher Tor1p activity contributes to 
the phenotypes presented by this mutant or TORC1 downregulation attenuates the 
deleterious effects of Sch9p activation, including mitochondrial dysfunction (Figure 17). 
Since TORC1 is a negative regulator of the expression of subunits of the respiratory 
chain in mitochondria (Bonawitz, Chatenay-Lapointe et al. 2007), its activation may 
impair the capacity of ncr1Δ cells to respire. The analysis of Sch9p phosphorylation in 
the C-terminal mediated by TORC1, as previously described (Urban, Soulard et al. 
2007), could give us an indication of changes in the activity of this protein complex in 
ncr1Δ cells. 
Taken together, these results implicate Sit4p and TORC1 in the mitochondrial 
dysfunctions and reduced lifespan presented by Ncr1p deficient cells. Also, this work 
gives further insight regarding the molecular mechanisms behind sphingolipid 
homeostasis, autophagy, stress resistance and lifespan in the yeast model of NPC1. 
Being yeast a valuable scientific tool, with metabolic pathways conserved in mammals, 
data from this work can further help to understand the NPC1 pathology  
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